Oric Pharmaceuticals, Inc. (ORIC) stock
ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.00+0.48 (+6.38%)
Close on Nov 17, 2026Market cap $829.22MP/E –Yield –
Oric Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Oric Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$156.14M. For fiscal 2025 it was -$143.00M. The highest annual figure on record is -$22.37M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$143.00M | – |
| FY2024 | Dec 31, 2024 | -$142.90M | – |
| FY2023 | Dec 31, 2023 | -$110.78M | – |
| FY2022 | Dec 31, 2022 | -$91.77M | – |
| FY2021 | Dec 31, 2021 | -$78.87M | – |
| FY2020 | Dec 31, 2020 | -$74.19M | – |
| FY2019 | Dec 31, 2019 | -$28.57M | – |
| FY2018 | Dec 31, 2018 | -$22.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$45.30M | – |
| Q1 FY2026 | Mar 31, 2026 | -$39.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$32.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$36.02M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.43M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.36M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.35M | – |
See a number that looks wrong?